EUVIMEDEUVIMED entdecken
CrossrefInfokarte

PKC δ Regulates Translation Initiation through PKR and eIF2 α in Response to Retinoic Acid in Acute Myeloid Leukemia Cells

Bulent Ozpolat, Ugur Akar, Ibrahim Tekedereli, S. Neslihan Alpay, Magaly Barria, Baki Gezgen, Nianxiang Zhang, Kevin Coombes, Steve Kornblau, Gabriel Lopez-Berestein

Leukemia Research and Treatment · 2012

DOI: 10.1155/2012/482905 ↗
AbstractBibliografische Angaben

Abstract

Translation initiation and activity of eukaryotic initiation factor-alpha (eIF2 α ), the rate-limiting step of translation initiation, is often overactivated in malignant cells. Here, we investigated the regulation and role of eIF2 α in acute promyelocytic (APL) and acute myeloid leukemia (AML) cells in response to all- trans retinoic acid (ATRA) and arsenic trioxide (ATO), the front-line therapies in APL. ATRA and ATO induce Ser-51 phosphorylation (inactivation) of eIF2 α , through the induction of protein kinase C delta (PKC δ ) and PKR, but not other eIF2 α kinases, such as GCN2 and PERK in APL (NB4) and AML cells (HL60, U937, and THP-1). Inhibition of eIF2 α reduced the expression of cellular proteins that are involved in apoptosis (DAP5/p97), cell cycle (p21Waf1/Cip1), differentiation (TG2) and induced those regulating proliferation (c-myc) and survival (p70S6K). PI3K/Akt/mTOR pathway is involved in regulation of eIF2 α through PKC δ /PKR axis. PKC δ and p-eIF2 α protein expression levels revealed a significant association between the reduced levels of PKC δ ( P = 0.0378 ) and peIF2 ( P = 0.0041 ) and relapses in AML patients ( n = 47 ). In conclusion, our study provides the first evidence that PKC δ regulates/inhibits eIF2 α through induction of PKR in AML cells and reveals a novel signaling mechanism regulating translation initiation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →